NEW YORK, Oct. 29 /PRNewswire/ — See video from Roche
Pharmaceuticals at:
Roche announced on October 29 that the European Commission has
approved the use of MabThera (rituximab) as a maintenance treatment
for people suffering from follicular lymphoma who have responded to
initial induction therapy. The approval of MabThera maintenance
expands effective treatment options for people with this common
type of incurable blood cancer, doubling the likelihood of them
living longer without their disease worsening. Maintenance
treatment is an important approach to blood cancer management as it
reduces the risk of relapse and the use of repeated chemotherapy,
ultimately improving the lives of follicular lymphoma patients.
Available video includes expert’s opinion on MabThera.
About thenewsmarket.com
thenewsmarket.com delivers free broadcast- and streaming-quality
video and multimedia content directly to media around the world,
24/7. More than 25,000 media outlets in 190+ countries use
thenewsmarket.com, including the AP, BBC, CNBC, CNN, France 24,
N24, nytimes.com, RAI, TVE and ZDF.
Registered journalists can access video, audio, text, graphics
and photos at http://www.thenewsmarket.com.
If you are not already registered, please take a moment to sign
up – registration is quick and free: http://www.thenewsmarket.com/registration
Story Id: 20278
‘/>”/>
